Lactylation‐Driven HECTD2 Limits the Response of Hepatocellular Carcinoma to Lenvatinib
Advanced Science · 2025-04 · 12 (15)
DOI: 10.1002/advs.202412559 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 20.02.2025. Verfasst von Runyu Dong und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Quinolines, Phenylurea Compounds. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, USTC Research Funds of the Double First-Class Initiative, Natural Science Foundation of Anhui Education Department for Distinguished Young Scholars.
Abstract (Originalsprache)
Drug resistance remains a major hurdle for the therapeutic efficacy of lenvatinib in hepatocellular carcinoma (HCC). However, the underlying mechanisms remain largely undetermined. Unbiased proteomic screening is performed to identify the potential regulators of lenvatinib resistance in HCC. Patient‐derived organoids, patient‐derived xenograft mouse models, and DEN/CCl 4 induced HCC models are constructed to evaluate the effects of HECTD2 both in vitro and in vivo. HECTD2 is found to be highly expressed in lenvatinib‐resistant HCC cell lines, patient tissues, and patient‐derived organoids and xenografts. In vitro and in vivo experiments demonstrated that overexpression of HECTD2 limits the response of HCC to lenvatinib treatment. Mechanistically, HECTD2 functions as an E3 ubiquitin ligase of KEAP1, which contributes to the degradation of KEAP1 protein. Subsequently, the KEAP1/NRF2 signaling pathway initiates the antioxidative response of HCC cells. Lactylation of histone 3 on lysine residue 18 facilitates the transcription of HECTD2. Notably, a PLGA‐PEG nanoparticle‐based drug delivery system is synthesized, effectively targeting HECTD2 in vivo. The NPs achieved tumor‐targeting, controlled‐release, and biocompatibility, making them a promising therapeutic strategy for mitigating lenvatinib resistance. This study identifies HECTD2 as a nanotherapeutic target for overcoming lenvatinib resistance, providing a theoretical basis and translational application for HCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.
- Department of Gastrointestinal Surgery, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu, 241000, China.
- Department of Oncology, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu, 241000, China.
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu, 241000, China.
- Anhui Province Key Laboratory of Non-coding RNA Basic and Clinical Transformation, Wannan Medical College, Wuhu, 241000, China.
- Department of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.
ORCID-Profile: Yao Fei, Xueliang Zuo
Förderung
- National Natural Science Foundation of China
- USTC Research Funds of the Double First-Class Initiative
- Natural Science Foundation of Anhui Education Department for Distinguished Young Scholars
- Natural Science Foundation of Anhui Education Department for Excellent Young Scholars
- Natural Science Research Project of Anhui Education Department
- Natural Science Foundation of the Jiangsu Higher Education Institutions of China
- Provincial Quality Engineering Project of Anhui Education Department
Zitieren
APA
Dong, R., Fei, Y., He, Y., Gao, P., Zhang, B., Zhu, M., Wang, Z., Wu, L., Wu, S., Wang, X., Cai, J., Chen, Z., & Zuo, X. (2025). Lactylation‐Driven HECTD2 Limits the Response of Hepatocellular Carcinoma to Lenvatinib. Advanced Science, 12(15). https://doi.org/10.1002/advs.202412559
Vancouver
Dong R, Fei Y, He Y, Gao P, Zhang B, Zhu M, et al. Lactylation‐Driven HECTD2 Limits the Response of Hepatocellular Carcinoma to Lenvatinib. Advanced Science. 2025;12(15). doi:10.1002/advs.202412559
BibTeX
@article{Dong2025,
author = {Dong, Runyu and Fei, Yao and He, Yiren and Gao, Peng and Zhang, Bo and Zhu, Menglin and Wang, Zhixiong and Wu, Longfei and Wu, Shuai and Wang, Xiaoming and Cai, Juan and Chen, Zhiqiang and Zuo, Xueliang},
title = {Lactylation‐Driven HECTD2 Limits the Response of Hepatocellular Carcinoma to Lenvatinib},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {15},
doi = {10.1002/advs.202412559}
}
EUVIMED